ELTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 May 2024 @ 16:00):

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases...

Stats
Today's Volume	45 099.00
Average Volume	55 591.00
Market Cap	106.41M
EPS	$0 ( 2024-04-05 )
Next earnings date	( $-1.090 ) 2024-08-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.490
ATR14	$0.0380 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-19	Chudnovsky Yekaterina	Buy	1 032 702	Pre-Funded Common Stock Purchase Warrant
2024-02-01	Piekos Brian	Buy	43 225	Stock Option (right to buy)
2024-02-01	Connelly Robert	Buy	225 137	Stock Option (right to buy)
2024-02-01	Haqq Christopher	Buy	28 200	Stock Option (right to buy)
2024-02-01	Demuth Peter	Buy	29 800	Stock Option (right to buy)

INSIDER POWER
100.00
Last 6 transactions
Buy: 1 359 406 \| Sell: 0

Volume Correlation

Long: -0.08 (neutral)

Short: 0.97 (very strong)

Signal:(53.729) Expect same movement, but be aware

Elicio Therapeutics, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Elicio Therapeutics, Inc. Correlation - Currency/Commodity

0.23
( neutral )

-0.59
( weak negative )

0.00
( neutral )

-0.08
( neutral )

0.48
( neutral )

0.49
( neutral )

Elicio Therapeutics, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-88.84

FY	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-88.84

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.930

FY	2019
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.505

Financial Reports:

No articles found.

Elicio Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.

Realtime updates for Elicio Therapeutics, Inc. [ELTX]

Upcoming Earnings Alert

Elicio Therapeutics, Inc. Options Data

Calls

Puts